A phase II basket trial evaluating the efficacy of tasurgratinib (E7090) in patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE study.
A phase II basket trial evaluating the efficacy of tasurgratinib (E7090) in patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE study.
Kazumi Kurishita, Ryo Sadachi, Hitomi Sumiyoshi Okuma, Kan Yonemori et al.
Citations
1 citations
Journal
Journal of Clinical Oncology
Topics
Fibroblast Growth Factor Research
Field-Weighted Citation Impact (FWCI)
0.81
article
A phase II basket trial evaluating the efficacy of tasurgratinib (E7090) in patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE study.
Tohoku University Hospital (JP), Kyushu University Hospital (JP), Hokkaido University Hospital (JP), National Cancer Center Hospital East (JP), Kyoto University Hospital (JP), Tokyo National Hospital (JP)